share_log

Allarity Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Allarity Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Allarity Therapeutics | PRE 14A：並購重組委托聲明
美股SEC公告 ·  06/21 16:47

Moomoo AI 已提取核心訊息

Allarity Therapeutics, Inc. announced a series of amendments to its Certificate of Incorporation, which were approved during the Annual Meeting of Stockholders held on July 26, 2024. The amendments include a reduction in the number of authorized shares from 750,500,000 to 250,500,000 and a decrease in common stock from 750,000,000 to 250,000,000. Additionally, provisions were made to allow for the exculpation of certain officers in specific circumstances, as permitted by law. The amendments are part of a strategic effort to streamline the company's share structure and align with corporate governance practices. The changes were approved by the affirmative vote of the majority of the outstanding shares of the company's common stock entitled to vote. The board of directors had previously adopted resolutions declaring the amendments advisable and in the best interests of the company and its stockholders. The amendments are expected to provide the company with the flexibility to issue shares as needed for general corporate purposes and to potentially reduce future litigation costs associated with frivolous lawsuits.
Allarity Therapeutics, Inc. announced a series of amendments to its Certificate of Incorporation, which were approved during the Annual Meeting of Stockholders held on July 26, 2024. The amendments include a reduction in the number of authorized shares from 750,500,000 to 250,500,000 and a decrease in common stock from 750,000,000 to 250,000,000. Additionally, provisions were made to allow for the exculpation of certain officers in specific circumstances, as permitted by law. The amendments are part of a strategic effort to streamline the company's share structure and align with corporate governance practices. The changes were approved by the affirmative vote of the majority of the outstanding shares of the company's common stock entitled to vote. The board of directors had previously adopted resolutions declaring the amendments advisable and in the best interests of the company and its stockholders. The amendments are expected to provide the company with the flexibility to issue shares as needed for general corporate purposes and to potentially reduce future litigation costs associated with frivolous lawsuits.
Allarity Therapeutics公司宣佈在2024年7月26日舉行的股東年會上通過了一系列公司章程修正案。修正案包括將授權股票數量從7.505億股減少到2.505億股和普通股股本從7.5億股減少到2.5億股。此外，根據法律規定，修正案中還規定了在特定情況下允許某些高管免責的條款。修正案是公司爲簡化股權結構和與企業治理實踐相一致而作出的戰略努力的一部分。修正案由公司普通股的優先投票股權的多數股票支持通過。董事會此前已通過決議宣佈修正案可行且符合公司及其股東的最佳利益。修正案預計將爲公司提供靈活性，在需要時發行股票以用於普通企業目的，並在可能降低與無聊的訴訟有關的未來訴訟成本。
Allarity Therapeutics公司宣佈在2024年7月26日舉行的股東年會上通過了一系列公司章程修正案。修正案包括將授權股票數量從7.505億股減少到2.505億股和普通股股本從7.5億股減少到2.5億股。此外，根據法律規定，修正案中還規定了在特定情況下允許某些高管免責的條款。修正案是公司爲簡化股權結構和與企業治理實踐相一致而作出的戰略努力的一部分。修正案由公司普通股的優先投票股權的多數股票支持通過。董事會此前已通過決議宣佈修正案可行且符合公司及其股東的最佳利益。修正案預計將爲公司提供靈活性，在需要時發行股票以用於普通企業目的，並在可能降低與無聊的訴訟有關的未來訴訟成本。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間